AKLI
- Akili, Inc.
()
Overview
Company Summary
Akili, Inc. (AKLI) is a company that specializes in the development and distribution of digital therapeutics. Digital therapeutics are software-based medical treatments designed to address various health conditions. AKLI focuses specifically on developing these digital therapeutics for cognitive health conditions, including attention-deficit/hyperactivity disorder (ADHD) and Autism Spectrum Disorder (ASD).
AKLI utilizes cutting-edge technology and evidence-based approaches to create interactive and engaging video games that are clinically proven to improve cognitive function and mental health. These digital therapeutics tap into the brain's neuroplasticity, helping individuals develop and enhance cognitive skills such as attention, working memory, and executive functioning.
The company's flagship product, EndeavorRx, is the first prescription digital therapeutic approved by the US Food and Drug Administration (FDA) to improve attention function in children with ADHD. It is a video game specifically designed to target and improve different cognitive skills. Patients can access EndeavorRx through a prescription from their healthcare provider and play the game on a designated platform, such as a tablet or smartphone.
Akili also conducts rigorous clinical trials and collaborates with leading researchers and medical professionals to validate the efficacy and safety of their digital therapeutics. They aim to provide accessible, evidence-based treatments for cognitive health conditions that reduce the reliance on traditional pharmaceutical interventions.
Overall, Akili, Inc. focuses on leveraging technology to provide innovative digital solutions that improve cognitive health and function, with a particular focus on conditions like ADHD and ASD. Their goal is to revolutionize the field of healthcare by offering alternative treatment options that are engaging, effective, and personalized.